UPCOMING LIVE WEBINAR
The R&D Tax Credit in the Pharmaceuticals, Medical Devices and Healthcare Industry
Date and Time: There are no webinars running at this time
R&D Tax Credits: 80% of eligible companies don’t claim! Every year, companies waste thousands or even hundreds of thousands of euros due to simple misunderstandings about the Research & Development (R&D) tax credit. Amended claims can go back several years and in most cases generate considerable refunds for past R&D activities.
WEBINAR DETAILS
Title: The R&D Tax Credit in the Pharmaceuticals, Medical Devices and Healthcare
Date: There are no webinars running at this time
Time: There are no webinars running at this time
Cost: FREE
Learning Objectives include:
- An Overview of the Irish R&D Tax Credit framework (Section 766)
- Identify Qualifying Research Activities
- Define the Core Eligibility Criteria
- How to Substantiate Activities through Documentation
- Identify Qualifying Research Expenses
Knowledge Level: Basic*
Our Difference
- We care about the price – Our rates are the most competitive on the market.
- We care about the risk – We are one of the most cautious, if not the most cautious, R&D tax credit providers on the market.
- We are here to stay – We are one of the largest specialized R&D tax credit firms in Ireland. We exclusively provide R&D tax credit services and take a long-term view.
- We think we’re the best – We do one thing, and we do it better than anyone else because it’s the only thing we do.
Founded in 1984

Cybersecurity Accredited

Risk Management Accredited

| Framework Element | Description | Implication for Clients |
| Six-Eye Review | A mandatory internal review of every claim by a qualified Engineer, Scientist, and Tax Professional. | Ensures the claim is technically valid, financially accurate, and compliant with tax law, maximizing its defensibility. |
| ISO 31000:2009 (Risk Management) | An international certification for the firm’s comprehensive risk management policies and processes. | Provides objective third-party validation of the firm’s commitment to mitigating tax risk for the client. |
| ISO 27001 (Information Security) | A global benchmark standard for establishing and maintaining an Information Security Management System (ISMS). | Guarantees the highest level of protection for sensitive intellectual property and confidential financial data. |
Small businesses in the pharmaceutical sector can significantly benefit from the R&D Tax Credit, transforming their innovative efforts into substantial tax savings. This credit directly reduces Corporation Tax liability, freeing up capital that can be reinvested in further research, development of new drugs, medical devices, or improved manufacturing processes. Crucially, eligible startups and pre-revenue companies can utilize the refundable cash credit payable over three annual instalments. This immediate cash benefit offsets personnel costs, providing vital liquidity for young companies that often operate at a loss while pursuing groundbreaking pharmaceutical advancements.
Pharmaceutical Case Study
Pharmaceutical companies are constantly working to develop innovative medicines and therapies that improve patient outcomes and address unmet medical needs. This process involves extensive research and development (R&D), including drug discovery, chemical synthesis, preclinical testing, and clinical trials. However, these efforts are often extremely costly and time-consuming, with no guarantee of success. R&D tax credits under Section 766 offer a critical financial incentive that helps pharmaceutical companies offset some of these high costs, allowing them to reinvest in further innovation. By reducing the effective cost of research activities, these credits enable companies to pursue more ambitious and risk-intensive projects that might otherwise be financially unfeasible. For the pharmaceutical industry, R&D tax credits can significantly accelerate the pace of innovation. They encourage continued investment in new drug development, support the creation of cutting-edge treatments, and foster collaboration with academic institutions, research centers, and biotechnology startups. Additionally, these credits can enhance a company’s global competitiveness by improving cash flow and reducing tax liabilities, which is particularly valuable in a sector where long development timelines and regulatory hurdles can delay returns on investment. In a rapidly evolving healthcare landscape, where demand for effective and personalized medicine is growing, the R&D tax credit plays a vital role in sustaining pharmaceutical advancement. It not only supports the discovery of life-saving treatments but also contributes to job creation, economic growth, and public health, provided that companies maintain robust documentation for potential audits by the Irish Revenue Commissioners.





























